Prefer Dr Reddys, Sun Pharma: Suresh Mahadevan

Suresh Mahadevan, MD & Head of Indian Equities at UBS Securities told CNBC-TV18, "In the pharma sector we are not very positive on Ranbaxy Laboratories, our analysts like most of the other names except Ranbaxy. It is partly to do with this but generally we prefer other names like Dr Reddys Laboratories, Sun Pharma, etc. over Ranbaxy."

At 13:07 hrs Dr Reddys Laboratories was quoting at Rs 2,064.25, down Rs 16.70, or 0.80 percent. It has touched an intraday high of Rs 2,119.90 and an intraday low of Rs 2,049.95.
The share touched its 52-week high Rs 2,150.90 and 52-week low Rs 1,555.00 on 13 May, 2013 and 19 June, 2012, respectively. Currently, it is trading 4.03 percent below its 52-week high and 32.75 percent above its 52-week low. Market capitalisation stands at Rs 35,058.49 crore.